United Therapeutics Corp
UTHR
View Detailed Chart
440.000USD
-5.380-1.21%
Close 10/10, 16:00（ET）Quotes delayed by 15 min
19.89BMarket Cap
16.02P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.21%
5 Days
-2.88%
1 Month
+8.68%
6 Months
+56.49%
Year to Date
+24.70%
1 Year
+22.83%
View Detailed Chart
TradingKey Stock Score of United Therapeutics Corp
Currency: USD Updated: 2025-10-10Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
United Therapeutics Corp's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
16
analysts
Buy
Current Rating
489.804
Target Price
+9.97%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
United Therapeutics Corp Highlights
StrengthsRisks
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 48.60% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 64.32.
Overvalued
The company’s latest PE is 15.89, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 44.91M shares, decreasing 6.50% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 14.70K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.70.
Financial Indicators
EPS
No Data
Total revenue
No Data
United Therapeutics Corp Info
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Ticker SymbolUTHR
CompanyUnited Therapeutics Corp
CEODr. Martine A. Rothblatt
Websitehttps://www.unither.com/
Related Instruments
-2.53%
-0.19%
-0.04%
-0.60%
-0.79%
-1.69%
-2.98%
-1.79%
+0.38%
-1.76%
-1.50%
-1.70%
+0.75%
+0.22%
-1.59%
-0.28%
0.00%
-1.59%
+0.70%
-0.92%Popular Symbols
